Low-dose nivolumab in advanced hepatocellular carcinoma
Số trang: 12
Loại file: pdf
Dung lượng: 2.11 MB
Lượt xem: 11
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
The approved dose of nivolumab is 3mg/kg or a fat dose of 240mg for indications. There is no doseresponse relationship for nivolumab; therefore, a low-dose regimen may be an option to reduce financial toxicity. This study was designed to investigate the efcacy and safety of low-dose nivolumab in the management of hepatocellular carcinoma (HCC).
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Low dose Hepatocellular carcinoma Hepatocellular carcinoma Financial toxicity Immune checkpoint inhibitorsGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 118 0 0 -
12 trang 93 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 43 0 0
-
12 trang 38 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 37 0 0